Search Results for "vaccine, adult"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, adult. Results 251 to 260 of 293 total matches.
See also: MMR II

Tapinarof Cream (Vtama) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
(AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist ...
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be approved by the FDA.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):122-4 |  Show IntroductionHide Introduction

An EUA for Bebtelovimab for Treatment of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
the emergence of the Omicron variant. In one cohort, 380 unvaccinated, mostly low-risk adults were randomized ...
The investigational monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease, including hospitalization and death, and for whom alternative treatment options are unavailable or inappropriate. Bebtelovimab is active against the Omicron variant of SARS-CoV-2; sotrovimab (VIR-7831) is the only other monoclonal antibody currently available for treatment of COVID-19 that is active...
Med Lett Drugs Ther. 2022 Mar 21;64(1646):41-2 |  Show IntroductionHide Introduction

Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
years (estimated prevalence 40 cases per 100,000 persons).2 EoE is thought to be an abnormal immune ...
Eohilia (Takeda), an oral suspension formulation of the corticosteroid budesonide, has been approved by the FDA for treatment of eosinophilic esophagitis (EoE) in patients ≥11 years old. It is the first oral drug to be approved in the US for this indication. The subcutaneously injected interleukin (IL)-4 receptor antagonist dupilumab (Dupixent) is approved for treatment of EoE in patients ≥1 year old who weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5   doi:10.58347/tml.2024.1704c |  Show IntroductionHide Introduction

Vedolizumab (Entyvio) for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014  (Issue 1451)
to severe ulcerative colitis or Crohn’s disease in adults who have not responded to, lost response ...
The FDA has approved vedolizumab (Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri), another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.
Med Lett Drugs Ther. 2014 Sep 15;56(1451):86-8 |  Show IntroductionHide Introduction

Monoclonal For Gram-Negative Sepsis

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 1991  (Issue 856)
). Human J5 immune plasma also protected against gram-negative shock and death when given prophylactically ...
HA-1A (Centoxin - Centocor), a monoclonal IgM antibody against endotoxin from gram-negative bacteria, may soon be approved for marketing by the US Food and Drug Administration. Commercially available in Europe, HA-1A has been used in the USA as an investigational drug. E5 (Xomen - Xoma), another monoclonal IgM antibody against endotoxin, is also available here for investigational use.
Med Lett Drugs Ther. 1991 Nov 1;33(856):103-4 |  Show IntroductionHide Introduction

Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
on the results of an open-label trial in 155 adults with relapsed or refractory DLBCL, not otherwise specified ...
Glofitamab-gxbm (Columvi – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for IV treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or large B-cell lymphoma (LBCL) arising from follicular lymphoma after ≥2 lines of systemic therapy. Accelerated approval was based on response rates and durability of response. Glofitamab is the second T-cell-engaging bispecific antibody to be approved in the US for treatment of DLBCL; epcoritamab-bysp (Epkinly), which is given...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e129-30   doi:10.58347/tml.2023.1682b |  Show IntroductionHide Introduction

Biktarvy - Another INSTI-Based Combination for HIV

   
The Medical Letter on Drugs and Therapeutics • Aug 13, 2018  (Issue 1553)
), for treatment of HIV-1 infection in adults. The new combination is indicated for use in patients who ...
The FDA has approved Biktarvy (Gilead), a once-daily, fixed-dose combination of bictegravir, a new integrase strand transfer inhibitor (INSTI), and the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir alafenamide (TAF), for treatment of HIV-1 infection in adults. The new combination is indicated for use in patients who are antiretroviral-naive or who have been virologically suppressed on a stable antiretroviral regimen for ≥3 months with no history of treatment failure and no known substitutions associated with resistance to any component of the...
Med Lett Drugs Ther. 2018 Aug 13;60(1553):132-5 |  Show IntroductionHide Introduction

Dupilumab (Dupixent) for Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019  (Issue 1563)
-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis ...
The FDA has approved the subcutaneously injected monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis inadequately controlled with topical therapies.
Med Lett Drugs Ther. 2019 Jan 14;61(1563):6-8 |  Show IntroductionHide Introduction

Voclosporin (Lupkynis) for Lupus Nephritis

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
mofetil (Cellcept, and generics) and a corticosteroid for treatment of adults with active lupus ...
Voclosporin (Lupkynis – Aurinia), an oral calcineurin inhibitor, has been approved by the FDA for use in combination with the antimetabolite immunosuppressant mycophenolate mofetil (Cellcept, and generics) and a corticosteroid for treatment of adults with active lupus nephritis. It is the first calcineurin inhibitor to be approved in the US for this indication. Tacrolimus (Prograf, and others) and cyclosporine (Neoral, and others), the other available systemic calcineurin inhibitors, are approved for prophylaxis of organ rejection in transplant patients.
Med Lett Drugs Ther. 2021 Aug 23;63(1631):134-6 |  Show IntroductionHide Introduction

Statins and Diabetes Risk

   
The Medical Letter on Drugs and Therapeutics • Sep 01, 2014  (Issue 1450)
an immune response that interferes with insulin signaling.2 NEW-ONSET DIABETES RISK — A meta-analysis ...
In 2012, the FDA required manufacturers of HMG-CoA reductase inhibitors (statins) to add a warning to their labels about reports of increased blood glucose and glycosylated hemoglobin (HbA1c) levels. Since then, several new studies have been published.
Med Lett Drugs Ther. 2014 Sep 1;56(1450):79-80 |  Show IntroductionHide Introduction